Activated T cell subsets in human type 1 diabetes: Evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 472-482

  Baker, C ^a   Chang, L ^b   Elsegood, K A ^b   Bishop, A J ^b   Gannon, D H ^b   Narendran, P ^c   Leech, N J ^d   Dayan, C M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Activated T cells; CD30; Diabetes; DR; Human

Indexed keywords

CD134 ANTIGEN; CD30 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD44V6 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMAGNETIC SEPARATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, CD3; ANTIGENS, CD30; CYTOKINES; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPHOCYTE ACTIVATION; MALE; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 33846807498     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03307.x     Document Type: Article

References (48)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358:221-9.
2. Gardner SG, Gale EA, Williams AJ et al. Progression to diabetes in relatives with islet autoantibodies. Is it inevitable? Diabetes Care 1999; 22:2049-54.
3. Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 1997; 46:1701-10.
4. Achenbach P, Warncke K, Reiter J et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53:384-92.
5. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia 2003; 46:305-21.
6. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749-53.
7. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.N Engl J Med 2002; 346:1692-8.
8. Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001; 14 (Suppl. 1):619-22.
9. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003; 52:1059-65.
10. Tanaka T, Ebisuno Y, Kanemitsu N et al. Molecular determinants controlling homeostatic recirculation and tissue-specific trafficking of lymphocytes. Int Arch Allergy Immunol 2004; 134:120-34.
11. Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol 2000; 18:561-92.
12. Wong FS, Karttunen J, Dumont C et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999; 5:1026-31.
13. Trudeau JD, Kelly-Smith C, Verchere CB et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003; 111:217-23.
14. Dayan CM, Londei M, Corcoran AE et al. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proc Natl Acad Sci USA 1991; 88:7415-19.
15. Mullins RJ, Cohen SB, Webb LM et al. Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. J Clin Invest 1995; 96:30-7.
16. Bischof F, Hofmann M, Schumacher TN et al. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol 2004; 172:2878-84.
17. Shimoda S, Van de Water J, Ansari A et al. Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998; 102:1831-40.
18. Callan MF, Tan L, Annels N et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187:1395-402.
19. Bieganowska K, Hollsberg P, Buckle GJ et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunol 1999; 162:1765-71.
20. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000; 165:1641-51.
21. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203-8.
22. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-63.
23. Reijonen H, Novak EJ, Kochik S et al. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002; 51:1375-82.
24. Kotzin BL, Falta MT, Crawford F et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000; 97:291-6.
25. Tan LC, Gudgeon N, Annels NE et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162:1827-35.
26. Dosch HM, Becker DJ. Measurement of T-cell autoreactivity in autoimmune diabetes. Diabetologia 2000; 43:386-7.
27. Roep BO. Autoreactive T cells in endocrine/organ-specific autoimmunity: why has progress been so slow? Springer Semin Immunopathol 2002; 24:261-71.
28. Mazza G, Ponsford M, Lowrey P, Campbell MJ, Zajicek J, Wraith DC. Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol 2002; 128:538-47.
29. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19:568-74.
30. De Berardinis P, Londei M, Kahan M et al. The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+. Clin Exp Immunol 1988; 73:255-9.
31. Bingley PJ, Bonifacio E, Shattock M et al. Can islet cell antibodies predict IDDM in the general population? Diabetes Care 1993; 16:45-50.
32. Gillespie KM, Valovin SJ, Saunby J et al. HLA class II typing of whole genome amplified mouth swab DNA. Tissue Antigens 2000; 56:530-8.
33. Biswas P, Galli A, Capiluppi B, Ciuffreda D, Lazzarin A, Tambussi G. Selective enrichment of CD30-expressing cells within the blast region of lymphocytes from patients with primary HIV infection (PHI). J Biol Regul Homeost Agents 2002; 16:33-6.
34. Hehmke B, Michaelis D, Gens E, Laube F, Kohnert KD. Aberrant activation of CD8+ T-cell and CD8+ T-cell subsets in patients with newly diagnosed IDDM. Diabetes 1995; 44:1414-19.
35. Peakman M, Leslie RD, Alviggi L, Hawa M, Vergani D. Persistent activation of CD8+ T-cells characterizes prediabetic twins. Diabetes Care 1996; 19:1177-84.
36. Kadziela K, Kowalska H, Rymkiewicz-Kluczynska B et al. Changes in lymphocyte subsets in children with newly diagnosed type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16:185-91.
37. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+) CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-9.
38. Bengtsson A. The role of CD30 in atopic disease. Allergy 2001; 56:593-603.
39. Schwab U, Stein H, Gerdes J et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299:65-7.
40. Smith CA, Gruss HJ, Davis T et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73:1349-60.
41. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10:457-70.
42. Amakawa R, Hakem A, Kundig TM et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84:551-62.
43. Ellis TM, Simms PE, Slivnick DJ, Jack HM, Fisher RI. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol 1993; 151:2380-9.
44. Chan KW, Hopke CD, Krams SM, Martinez OM. CD30 expression identifies the predominant proliferating T lymphocyte population in human alloimmune responses. J Immunol 2002; 169:1784-91.
45. Agrawal B, Reddish M, Longenecker BM. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. J Immunol 1996; 157:3229-34.
46. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999; 398:341-4.
47. Siegmund T, Armitage N, Wicker LS, Peterson LB, Todd JA, Lyons PA. Analysis of the mouse CD30 gene: a candidate for the NOD mouse type 1 diabetes locus Idd9. 2 Diabetes 2000; 49:1612-16.
48. Chakrabarty S, Nagata M, Yasuda H et al. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol 2003; 133:318-25.